These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 7738660)

  • 21. Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RIT.
    DeNardo SJ; DeNardo GL; Yuan A; Richman CM; O'Donnell RT; Lara PN; Kukis DL; Natarajan A; Lamborn KR; Jacobs F; Siantar CL
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3938S-44S. PubMed ID: 14506192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts.
    DeNardo SJ; Kukis DL; Kroger LA; O'Donnell RT; Lamborn KR; Miers LA; DeNardo DG; Meares CF; DeNardo GL
    Proc Natl Acad Sci U S A; 1997 Apr; 94(8):4000-4. PubMed ID: 9108094
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Importance of temporal relationships in combined modality radioimmunotherapy of breast carcinoma.
    DeNardo SJ; Kroger LA; Lamborn KR; Miers LA; O'Donnell RT; Kukis DL; Richman CM; DeNardo GL
    Cancer; 1997 Dec; 80(12 Suppl):2583-90. PubMed ID: 9406713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CaNa2EDTA for improvement of radioimmunodetection and radioimmunotherapy with 111In and 90Y-DTPA-anti-CEA MAbs in nude mice bearing human colorectal cancer.
    Watanabe N; Oriuchi N; Endo K; Inoue T; Kuroki M; Matsuoka Y; Tanada S; Murata H; Kim EE; Sasaki Y
    J Nucl Med; 2000 Feb; 41(2):337-44. PubMed ID: 10688120
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Indium-111- and yttrium-90-labeled human monoclonal immunoglobulin M targeting of human ovarian cancer in mice.
    Borchardt PE; Quadri SM; Freedman RS; Vriesendorp HM
    J Nucl Med; 1998 Mar; 39(3):476-84. PubMed ID: 9529295
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biodistribution and radioimmunotherapy of human breast cancer xenografts with radiometal-labeled DOTA conjugated anti-HER2/neu antibody 4D5.
    Tsai SW; Sun Y; Williams LE; Raubitschek AA; Wu AM; Shively JE
    Bioconjug Chem; 2000; 11(3):327-34. PubMed ID: 10821648
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Yttrium-90 chimeric L6 therapy of human breast cancer in nude mice and apoptosis-related messenger RNA expression.
    DeNardo SJ; Gumerlock PH; Winthrop MD; Mack PC; Chi SG; Lamborn KR; Shen S; Miers LA; deVere White RW; DeNardo GL
    Cancer Res; 1995 Dec; 55(23 Suppl):5837s-5841s. PubMed ID: 7493356
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does paclitaxel (Taxol) given after (111)In-labeled monoclonal antibodies increase tumor-cumulated activity in epithelial cancers?
    Miers L; Lamborn K; Yuan A; Richman C; Natarajan A; DeNardo S; DeNardo G
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7158s-7163s. PubMed ID: 16203816
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo comparison of CHX-DTPA ligand isomers in athymic mice bearing carcinoma xenografts.
    Roselli M; Milenic DE; Brechbiel MW; Mirzadeh S; Pippin CG; Gansow OA; Colcher D; Schlom J
    Cancer Biother Radiopharm; 1999 Jun; 14(3):209-20. PubMed ID: 10850305
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibody.
    Wong JY; Thomas GE; Yamauchi D; Williams LE; Odom-Maryon TL; Liu A; Esteban JM; Neumaier M; Dresse S; Wu AM; Primus FJ; Shively JE; Raubitschek AA
    J Nucl Med; 1997 Dec; 38(12):1951-9. PubMed ID: 9430476
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 90Yttrium-labeled complementarity-determining-region-grafted monoclonal antibodies for radioimmunotherapy: radiolabeling and animal biodistribution studies.
    Govindan SV; Shih LB; Goldenberg DM; Sharkey RM; Karacay H; Donnelly JE; Losman MJ; Hansen HJ; Griffiths GL
    Bioconjug Chem; 1998; 9(6):773-82. PubMed ID: 9815172
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A facile, water-soluble method for modification of proteins with DOTA. Use of elevated temperature and optimized pH to achieve high specific activity and high chelate stability in radiolabeled immunoconjugates.
    Lewis MR; Raubitschek A; Shively JE
    Bioconjug Chem; 1994; 5(6):565-76. PubMed ID: 7873659
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vivo biodistribution of a humanized anti-Lewis Y monoclonal antibody (hu3S193) in MCF-7 xenografted BALB/c nude mice.
    Clarke K; Lee FT; Brechbiel MW; Smyth FE; Old LJ; Scott AM
    Cancer Res; 2000 Sep; 60(17):4804-11. PubMed ID: 10987290
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intralesional radiolabeled human monoclonal IgM in human tumor xenografts.
    Borchardt PE; Quadri SM; Freedman RS; Vriesendorp HM
    Radiother Oncol; 1997 Sep; 44(3):283-93. PubMed ID: 9380829
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preclinical comparison in AR4-2J tumor-bearing mice of four radiolabeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-somatostatin analogs for tumor diagnosis and internal radiotherapy.
    Froidevaux S; Heppeler A; Eberle AN; Meier AM; Häusler M; Beglinger C; Béhé M; Powell P; Mäcke HR
    Endocrinology; 2000 Sep; 141(9):3304-12. PubMed ID: 10965902
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Local hyperthermia and SR 4233 enhance the antitumor effects of radioimmunotherapy in nude mice with human colonic adenocarcinoma xenografts.
    Wilder RB; Langmuir VK; Mendonca HL; Goris ML; Knox SJ
    Cancer Res; 1993 Jul; 53(13):3022-7. PubMed ID: 8319209
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intratumoral radioimmunotherapy of a human colon cancer xenograft using a sustained-release gel.
    Ning S; Trisler K; Brown DM; Yu NY; Kanekal S; Lundsten MJ; Knox SJ
    Radiother Oncol; 1996 May; 39(2):179-89. PubMed ID: 8735485
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Maleimidocysteineamido-DOTA derivatives: new reagents for radiometal chelate conjugation to antibody sulfhydryl groups undergo pH-dependent cleavage reactions.
    Lewis MR; Shively JE
    Bioconjug Chem; 1998; 9(1):72-86. PubMed ID: 9460549
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preparation and radiolabeling of a lyophilized (kit) formulation of DOTA-rituximab with ⁹⁰Y and ¹¹¹In for domestic radioimmunotherapy and radioscintigraphy of non-Hodgkin's lymphoma.
    Gholipour N; Jalilian AR; Khalaj A; Johari-Daha F; Yavari K; Sabzevari O; Khanchi AR; Akhlaghi M
    Daru; 2014 Jul; 22(1):58. PubMed ID: 25074720
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?
    Vallabhajosula S; Kuji I; Hamacher KA; Konishi S; Kostakoglu L; Kothari PA; Milowski MI; Nanus DM; Bander NH; Goldsmith SJ
    J Nucl Med; 2005 Apr; 46(4):634-41. PubMed ID: 15809486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.